Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, appointed Kathy Spencer-Pike chief commercial officer. Spencer-Pike has decades of commercial experience at McKesson, Novo Nordisk, Sanofi, and Pfizer. She will be responsible for accelerating the growth of the startup following its $56 million Series A in October.

Before Nucleus, Spencer-Pike was chief sales officer at McKesson where she spurred significant company growth, built a high-performance commercial team, and merged three legacy organizations into a single commercial organization achieving unprecedented double-digit growth year over year. She was previously vice president, commercial leader for Novo Nordisk, where she successfully led the planning, development and execution of market and sales strategies, exceeding revenue goals.

“Kathy’s sterling track record of enhancing organizational value, paired with her expertise in creating, developing, and leading high-achieving teams in new business, client success, and business expansion is the perfect addition to round out our C-Suite,” said Charles Conroy, CEO of Nucleus RadioPharma. “On the heels of our successful funding round to increase the radiopharmaceutical accessibility, we are eager to lean on Kathy’s experience and insight to accelerate further growth and advance our commitment to delivering life-saving treatments to patients with cancer.”